News

“Intas Pharmaceuticals brings down cancer treatment cost by 60%”

Intas-Pharmaceuticals

Intas Pharmaceuticals Limited, India’s one of the fastest growing pharmaceutical company, is pleased to announce a big step which will bring relief to large number of cancer patients in the country for whom the drug – Bevacizumab was out of reach till today. Intas’s bevacizumab therapy is priced at Rs. 39995 for the dose strength of 400mg variant which makes it 60% less than the currently available options.

Intas-Pharmaceuticals

Every year over 7 lakh patients die due to various types of cancer in India. At Intas we believe in the philosophy of “Patient First”. Hence, in order to relieve the patients from the financial burden associated with the treatment, thiscost effective measure is implemented by the organisation. The step is entirely focussed in making the drug treatment accessible to cancer patients in India thus, providing them with a beacon of hope in their fight against the disease.

Bevacizumab is a drug which works by slowing the growth of new blood vessels and is used in treating multiple-cancers like colorectal cancer, ovarian cancer, cervical cancer, lung cancer and recurrent glioblastoma (a type of brain tumour). The drug has been available in India since 2004 but the cost has been so prohibitive that as per eminent clinicians of the country they have been able to give this drug to very few eligible patients.

Don't be shellfish...Share on Facebook0Share on Google+0Share on LinkedIn0Share on StumbleUpon0Pin on Pinterest0Tweet about this on Twitter0
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>

Most Popular

To Top